English Archives - Page 18 of 20

ZICCUM AB engages Emerging Viral Diseases unit of Aix-Marseille University to develop dry viruses and vaccines, strengthening Ziccum”s future IP portfolio

Lund, 19^th December 2019. The Emerging Virus Unit (Unité des Virus Émergents) is one of the world"s leading virology laboratories. Ziccum has now engaged UVE to use Ziccum"s technology to develop and formulate vaccines and viruses as dry powders, boosting global access to them and making them significantly faster and cheaper to transport. This collaboration will significantly strengthen Ziccum"s IP portfolio.

"Underimmunisation has never been more urgent" says Ziccum CEO Göran Conradson "this decision by Unité des virus émergents (UVE) to collaborate and develop the use of our technology to see if it can make virus and vaccine materials easier and more cost-effective to transport worldwide is far-sighted and timely. We believe it could ultimately play a part in making vaccines more globally accessible."

UVE is one of the world"s leading virology labs and together with its partners they prepare and ship reference materials for vaccine development, academic research and diagnosis worldwide. Ziccum has engaged UVE in the company"s development of new dry versions of vaccines in the highly advanced laboratories (BSL3) available at UVE.

During an initial 18 month period UVE will formulate and test a wide range of viruses and vaccines as dry powders with an ultimate goal to make them transportable without any need for cold chain refrigeration.

"This gives us much prized access to UVE"s world-leading, high-safety BSL3 labs. That is a rare asset and will secure data and IP for Ziccum", continues Göran Conradson.

Since 2014 UVE has also coordinated the European Commission sponsored European Vaccine archive, which in 2020 will be a global consortium with 46 partner and associated partner labs across 21 countries. UVE will use LaminarPace to carry out stability testing, temperature analyses and more on the new dry-form viruses and vaccines.

Professor Remi Charrel, scientific head at UVE: "Ziccum technology has the potential to significantly improve the storage and shipping of virus samples, two key steps to promoting the distribution of high-quality biological material to support research in virology."

Ziccum CEO Göran Conradson: "The contract for the engagement with AMU has already been signed, with implementation pending a successful outcome to Ziccum"s ZICC TO 1 subscription option. A new range of tough, dry powder virus and vaccine materials that is faster and more cost-effective to transport could be a key part of solving the underimmunisation crisis. We"re very excited to move this project forward."

For more information about Ziccum, please contact:

Göran Conradson: CEO Ziccum AB
E-mail: conradson@ziccum.com

Mob: +46 709 61 55 99

About Ziccum

Ziccum AB (publ) develops new patented formulations of biological drugs where sensitivity to temperature differences, especially during transportation, currently limits medical and so commercial potential. The company"s patented technology, LaminarPace, develops dry powder formulations of drugs and vaccines that currently only exist in liquid form. By doing so Ziccum can increase the availability of drugs and vaccines in existing markets-and open up new ones.

Release

Market Notice 310/19 – Last day of trading in Ziccum AB subscription option ZICC TO 1

Last day of trading in the company’s subscription option, ZICC TO 1, is
December 20, 2019.

Information about the subscription option:
Shortname: ZICC TO 1
ISIN: SE0011641950
Orderbook-ID: 4NGA
CFI: RMXXXX
FISN: ZICCUM/OPT RTS 20191231
Last day of trading: December 20, 2019

Stockholm December 2, 2019

Spotlight Stock Market
08-511 68?000
trading@spotlightstockmarket.com

Läs som pdf

ZICCUM AB Third Quarter Report, 2019

Summary of Interim Third Quarter Report 2019: Ziccum well on way to delivering promises made during listing.

Summary of interim report – third quarter 2019

Ziccum is well on its way to delivering on the promises made when we first listed our stock – that during the year we would start three projects to develop stable, dry vaccines and biological drugs. So far during 2019 we have entered into two industrial collaborations, one with a global pharmaceutical company. We have also filed a patent application for a very important component in the development of new vaccines – Adenovirus. We continue to work with leading industrial and academic players to further develop the technology and adapt it for large-scale industrial production of biological drugs and vaccines. This is to position us for future discussions about partnership.

Jul-Sep 2019

Net sales KSEK 0 (0)

Operating income KSEK -1,380 (-1,714)

Earnings per share before and after dilution SEK -0.23

(-0.62)

Jan-Sep 2019

Net sales KSEK 0 (192)

Operating profit KSEK -5,378 (-2,442)

Earnings per share before and after dilution SEK -0.90

(-0.93)

Significant events during the third quarter of 2019

Ziccum has hired additional staff with expertise in the formulation of vaccines
We received a special invitation to attend the Global Vaccine Summit in Brussels where several important new contacts were made
Ziccum, on behalf of a vaccine development company, will conduct a feasibility study development of stable vaccines. The preliminary study does not entail any financial compensation at this stage but aims to investigate the compatibility of Ziccum air drying capability with the company"s new formulation

Significant events during the reporting period (Jan-Sep) 2019

On January 10, 2019, Ziccum reported that the company had filed a patent application for its dry and temperature-stable formulation, which meets the WHO"s requirements for CTC status. The dry formulation (the "powder") generated by Ziccum"s technology in LaminarPace ™ dissolves quickly when sterile water is added and then vaccination or treatment can be performed
Final payment from the EU support for FORMBECC was received during the second quarter amounting to approximately SEK 315 thousand
Ziccum has been granted SEK 200,000 in research grants from Vinnova. The research grant should used to evaluate Ziccum"s method for preparing dry preparations of vaccines

Significant events after the reporting period

At the beginning of October, an agreement was concluded for evaluation with a global drug and vaccine company, where together we evaluate Ziccum"s technology to generate stable and temperature-stable vaccines

For more information about Ziccum, please contact:

Göran Conradson: CEO Ziccum AB
E-mail: conradson@ziccum.com

Mob: +46 709 61 55 99

About Ziccum

Ziccum AB (publ) develops new patented formulations of biological drugs where sensitivity to temperature differences, especially during transportation, currently limits medical and so commercial potential. The company’s patented technology, LaminarPace, develops dry powder formulations of drugs and vaccines that currently only exist in liquid form. By doing so Ziccum can increase the availability of drugs and vaccines in existing markets—and open up new ones.

This press release has been submitted for publication by the company"s CEO at. 08.00 (CET) on November 7, 2019.

Release

Dela rsrapport Q3 2019 2019-11-06 18 19 10 fmo

Ziccum enters into evaluation agreement with global pharmaceutical and vaccine company

Stockholm, October 3, 2019. Ziccum AB (publ) (‘Ziccum’) is to conduct an evaluation study with a global healthcare company engaged in researching and developing, vaccines and proteins to combat infectious diseases. The project will explore whether Ziccum’s air-drying capabilities could generate stable, dry-form vaccines for the company. 1-in-5 children worldwide currently do not receive even basic vaccines (WHO), and 1.5 million die every year from vaccine-preventable diseases.

“We’re very proud to be starting this pilot project for such a prestigious and committed pharma company”, says Ziccum CEO Göran Conradson. “It’s a global company based in Europe who is committed to helping people be healthier by supporting better access and care in more places around the world. If our technology could be a part of that we would of course be delighted.”

“The pilot project collaboration is the second in just months”, Ziccum’s Chairman Fredrik Sjövall points out. “We clearly told the market that our first-year goal as a listed company was to partner on three pilot studies looking at developing stable, dry form vaccines and biologics. We’ve delivered on that promise. This is the second industrial collaboration we have announced in just a couple of months, and we see growing commercial interest in LaminarPaceTM moving forward. The world’s need to be able to deliver vaccines beyond the cold chain, to where they’re really needed, is urgent and growing. We’re convinced that our proprietary LaminarPaceTM technology may come to play an important part”.

LaminarPace enables the air-drying of delicate biologic drugs such as proteins, peptides and vaccines at room temperature, keeping the active ingredient intact. This capability could enable the development of new, stable, dry powder formulations of vaccines and biologic therapies that do not require costly global refrigeration supply chains to be transported and administered coast-effectively to any climate in the world.

For more information about Ziccum, please contact:

Göran Conradson: CEO Ziccum AB

E-mail: conradson@ziccum.com

Mob: +46 709 61 55 99

About Ziccum

Ziccum AB (publ) develops new patented formulations of biological drugs where sensitivity to temperature differences, especially during transportation, currently limits medical and so commercial potential. The company’s patented technology, LaminarPace, develops dry powder formulations of drugs and vaccines that currently only exist in liquid form. By doing so Ziccum can increase the availability of drugs and vaccines in existing markets – and open up new ones. Ziccum’s share is traded on Spotlight Stockmarket. www.ziccum.com

The information above was provided for publication on October 3, 2019 (20.00 hours) by Ziccum AB (publ) according to EU Market Abuse Regulations, through the above contact person.

Release

ZICCUM AB Half Year Report Q2 2019

Summary of Half Year Report second quarter 2019: This has been an eventful year for Ziccum.

Summary of Half Year Report, second quarter 2019

2019 has been eventful for Ziccum: We have filed a patent application for an important component in the development of new vaccines, Adenovirus. This has resulted in several industrial players showing new interest in our technology. We also announced that we have entered into a Contract Research agreement with one of these companies, aimed at evaluating LaminarPace ™ in combination with their own project. In the second quarter we also got together groups of leading industrial and academic players to take part in developing dry formulations of many new vaccines and viruses, in the process furthering LaminarPace’s progress towards adapting to large-scale industrial production of biological drugs and vaccines. Consequently we are well on the way to delivering on the targets we set during our share listing – namely carrying out three pilot studies within one year to develop stable, dry vaccines and biological drugs.

April-June 2019

Net sales SEK 0 thousand (2) Net sales SEK 0 thousand (192)

Operating profit SEK -2,296 thousand (-573) Operating profit SEK -3,998 thousand (-728)

Earnings per share before and after dilution SEK -0.38 (-0.24)

January-June 2019

Net sales SEK 0 thousand (192)

Operating profit SEK -3,998 thousand (-728)

Earnings per share before and after dilution SEK -0.67 (-0.32)

Significant events during the reporting period (Jan-Jun) 2019

Ziccum reported on January 10, 2019 that the company filed a patent application for a dry, temperature-stable formulation of Adenovirus, so meeting WHO requirements for CTC status. The dry formulation ("the powder") generated by Ziccum"s technology LaminarPace ™ can be rapidly dissolved back into solution by the addition of sterile water, after which vaccination or treatment can be carried out.

Significant events after the reporting period

Ziccum will, on behalf of a vaccine development company, carry out a feasibility study on the development of stable vaccines. At this stage, the preliminary study does not entail any financial compensation, but aims to investigate the compatibility of Ziccum"s air-drying capability and the vaccine company"s new formulation.

Otherwise, no significant events have occurred after the reporting period

READ THE WHOLE REPORT HERE

For more information about Ziccum, please contact:

Göran Conradson: CEO Ziccum AB
E-mail: conradson@ziccum.com

Mob: +46 709 61 55 99

About Ziccum

Ziccum AB (publ) develops new patented formulations of biological drugs where sensitivity to temperature differences, especially during transportation, currently limits medical and so commercial potential. The company’s patented technology, LaminarPace, develops dry powder formulations of drugs and vaccines that currently only exist in liquid form. By doing so Ziccum can increase the availability of drugs and vaccines in existing markets—and open up new ones.

This press release has been submitted for publication by the company"s CEO at. 08.00 (CET) on August 21, 2018.

Release

Dela rsrapport Q2 2019 2019-08-19 13 10 12

Ziccum AB (publ) to carry out Proof-of-Concept feasibility study for pharma formulation company

(Stockholm July 2, 2019) Ziccum AB (publ) (“Ziccum”) is carrying out an early-stage feasibility study for an innovative pharma company.

The early-stage Proof of Concept study involves no financial exchange, but is to explore the compatibility of Ziccum’s air-drying capabilities with the company’s novel formulation. LaminarPace, Ziccum’s proprietary technology, air dries proteins, peptides and biologics at room temperature into stable, dry-form substances.

For more information about Ziccum, please contact:

Göran Conradson: CEO Ziccum AB

E-mail: conradson@ziccum.com

Mob: +46 709 61 55 99

About Ziccum

Ziccum AB (publ) develops new patented formulations of biological drugs where sensitivity to temperature differences, especially during transportation, currently limits medical and so commercial potential. The company’s patented technology, LaminarPace, develops dry powder formulations of drugs and vaccines that currently only exist in liquid form. By doing so Ziccum can increase the availability of drugs and vaccines in existing markets—and open up new ones.

The information above was provided by Ziccum AB (publ) through the above contact person, for publication on July 2, 2019.

Release

Ziccum receives research grant from Vinnova AB (publ)

Ziccum has received a 200,000 SEK research grant from Vinnova AB (publ). The research grant will be used to evaluate Ziccum"s method of producing vaccines in dry-powder form.

The evaluation will take place in the ‘TESTA Center’ laboratories in Uppsala in premises that comply with BSL2 (Biosafety Level 2) standards, the required standard for collaboration with industrial partners on vaccine development.

For more information about Ziccum, please contact:

Göran Conradson: CEO Ziccum AB

E-mail: conradson@ziccum.com

Mob: +46 709 61 55 99

About Ziccum

Ziccum AB (publ) develops new patented formulations of biological drugs where sensitivity to temperature differences, especially during transportation, currently limits medical and so commercial potential. The company’s patented technology, LaminarPace, develops dry powder formulations of drugs and vaccines that currently only exist in liquid form. By doing so Ziccum can increase the availability of drugs and vaccines in existing markets—and open up new ones.

The information above was provided by Ziccum AB (publ) through the above contact person, for publication on June 28, 2019.

Read as PDF.

Ziccum AB (publ) Flagging message (regulatory)

(Stockholm May 29, 2019) Ziccum AB (publ) received information on the change in the number of shares related to Inhalation Science AB"s sale of 400,000 shares on May 23, 2019.

Inhalation Science AB had 2 190 000 shares in Ziccum before the sale, corresponding to 36.5% of the capital and votes. After the transaction on May 23, the holding is 29.8%. The flagging message is published when the holding passes below 30% after the change in the number of shares in Ziccum.

PLEASE NOTE: This is an unofficial translation of the original notice, which is in Swedish. In case of discrepancies, the Swedish version shall prevail.

For more information about Ziccum, please contact:

Göran Conradson: CEO Ziccum AB

E-mail: conradson@ziccum.com

Mob: +46 709 61 55 99

About Ziccum

Ziccum AB (publ) develops new patented formulations of biological drugs where sensitivity to temperature differences, especially during transportation, currently limits medical and so commercial potential. The company’s patented technology, LaminarPace, develops dry powder formulations of drugs and vaccines that currently only exist in liquid form. By doing so Ziccum can increase the availability of drugs and vaccines in existing markets—and open up new ones.

The information above was provided by Ziccum AB (publ) through the above contact person, for publication on May 29, 2019.

Read as PDF.

Report from Ziccum AB (publ) Annual General Meeting, May 20, 2019

(Stockholm, Sweden, May 20, 2019.) Today, May 20, 2019, the Annual General Meeting was held for Ziccum AB (publ). Below is a summary of the decisions made. All decisions were made with the required majority.

PLEASE NOTE: This is an unofficial translation of the original notice, which is in Swedish. In case of discrepancies, the Swedish version shall prevail.

Dividend

The Annual General Meeting resolved to establish the presented income statement and balance sheet. It was also resolved at the Annual General Meeting that no dividend would be paid for the financial year 2018.

Discharge

The Board of Directors and the President were discharged from liability for the 2018 financial year.

Board, auditor and fees

Ola Chamber, Kristian Kierkegaard, Mattias Münnich and Fredrik Sjövall were re-elected as board members and Mikaela Bruhammar was newly elected. Fredrik Sjövall was re-elected as Chairman of the Board. It was resolved that the fee shall be SEK 150,000 to the Chairman of the Board and SEK 75,000 each to the other Board members.

Ernst & Young AB was elected to the auditing firm. Authorized public accountant Stefan Svensson will be the chief auditor. It was decided that remuneration to the auditor should be paid according to approved invoice.

Authorization for the Board to issue shares, convertibles or warrants

In accordance with the Board"s proposal, the Meeting resolved to authorize the Board of Directors, on one or more occasions before the next Annual General Meeting, with or without deviation from the shareholders" preferential rights, to decide on a new share issue or issue of convertibles or warrants. The issue may be made against cash payment, non-payment or set-off. The number of shares that may be issued, or, upon the issue of convertibles or warrants, additional after conversion or exercise, with the support of the authorization shall be limited to ten (10) percent of the number of shares outstanding at the time of this meeting.

Decision to change the seat

The Meeting resolved to amend the Articles of Association in such a way that the seat of the Board of Directors is changed from Huddinge municipality to the municipality of Lund.

Flemingsberg May 20, 2019

Ziccum AB (publ)

Board of Directors

For more information about Ziccum, please contact:

Göran Conradson: CEO Ziccum AB
E-mail: conradson@ziccum.com

Mob: +46 709 61 55 99

About Ziccum

Ziccum AB (publ) develops new patented formulations of biological drugs where sensitivity to temperature differences, especially during transportation, currently limits medical and so commercial potential. The company’s patented technology, LaminarPace, develops dry powder formulations of drugs and vaccines that currently only exist in liquid form. By doing so Ziccum can increase the availability of drugs and vaccines in existing markets—and open up new ones.

This press release was submitted for publication 20 May, 2019.

Read as PDF

1 2 3 … 15 16 17 18 19 20

Posts navigation